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Abstract
The complexity of the hepatitis C virus (HCV) infection is reflected in its therapy, and great 
efforts are needed from the patient and the physician to be successful in eliminating the infec-
tion. How HCV will progress depends a lot on patient characteristics and social factors, in 
addition to the timing of initiation, duration, and final results of the therapy. The first treat-
ment approved for patients with chronic hepatitis C was interferon (IFN) which had a sus-
tained viral response (SVR) rate in 20%. Due to side effects, the adherence to this treatment 
was limited and required a patient-tailored approach with various medical disciplines work-
ing together and intervening at the right time to minimize potential obstacles. The introduc-
tion of direct-acting antivirals (DAAs) has contributed to the advancement of HCV treatment. 
However, a major obstacle to wide use of DAAs is their high price which has largely limited 
access to treatment. Guidelines and recommendations on treatment of hepatitis C have been 
developed to assist physicians and other health care providers to determine priority. Despite 
that, the arrival of new oral therapies has been met with enthusiasm as shorter, simpler, safer 
treatment allows for the possibility of delivering antiviral therapy on a large scale.
Keywords: HCV treatment, patient-tailored approach, treatment development, treatment 
goals, treatment priority
1. Introduction
Nowadays, the complexity of HCV infection is reflected in its therapy, and great efforts are 
needed from the patient and the treating physician. As a chronic disease with potential progres-
sion to fibrosis and HCV-associated cirrhosis, therapy of HCV in patients with liver disease and 
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post-liver transplant patients represents a challenge for physicians. Initiation, duration, and 
final results of the therapy depend on various factors such as viral factors, patient character-
istics, and numerous social factors. The patient-tailored approach and close patient-physician 
cooperation as well as the role of various medical disciplines working together and intervening 
at the right time is important to decrease the potential barrier in the achieving an SVR.
2. HCV infection: complexity of infection
HCV is a single-stranded positive-sense RNA virus which belongs to the genus Hepacivirus of the 
Flaviviridae family. The most significant nonstructural (NS) proteins involved in virus replication 
include the NS3 helicase, NS3-NS4A serine protease, and the NS5B RNA-dependent RNA poly-
merase [1]. There are six known genotypes and a single known case of genotype 7 and more than 
50 subtypes. Because the highest prevalence of genotype 1 is found in the most of middle-income 
countries, many DAAs have been primarily developed for use in those countries. Some DAAs are 
effective against multiple HCV genotypes. They are less effective for genotype 3 and cirrhosis [2].
The most significant clinical problems of chronic hepatitis C (CHC) involve the development 
of liver cirrhosis, hepatocellular carcinoma (HCC), or the need for liver transplantation [3, 4]. 
Progression of liver disease is more likely in patients with older age, male sex, longer duration 
of infection, advanced histologic stage and grade, genotype 1, increased hepatic iron, con-
comitant liver disorders, HIV infection, and obesity [5]. As many as 74% of people suffer from 
extrahepatic manifestations, and fatigue is the most common symptom. There are immune 
complex–mediated extrahepatic complications, glomerulonephritis, lymphoproliferative 
disorders such as B-cell lymphoma and extrahepatic complications unrelated to immune-
complex injury (Sjögren’s syndrome, lichen planus, porphyria cutanea tarda, type-II diabetes 
mellitus, and the metabolic syndrome) [2].
Recurrence of HCV following liver transplant occurs in more than 95% of patients and rein-
fection occurs within 72 h [2]. Not all patients can receive therapy instantly on the approval 
of new agents, so priority should be given to those patients with the most urgent necessity 
[6]. About 80% of patients treated with interferon-based treatment experience adverse effects. 
Hence, the close monitoring, timely preventive, therapeutic measures, and patient motivation 
are needed. Furthermore, adverse effects vary between drugs and range from poor general 
well-being to specific conditions affecting hematopoiesis, skin, behavior, thyroid, eyes, or 
lungs, and therefore, a multidisciplinary approach is necessary [7].
3. HCV treatment options goals and timeline development
CHC caused by infection with HCV is one of the major causes of liver disease. The goal 
of hepatitis C treatment is to achieve SVR defined as no detectable HCV in blood at least 
12 weeks after finishing treatment. If a durable SVR can be achieved, the risks for liver-related 
morbidity and mortality are decreased [2].
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In infected patients, IFN-mediated immune response is associated with the induction of IFN-
stimulated genes (ISGs) in the liver [9] during the first 4–10 weeks of infection. This is fol-
lowed by an HCV-specific T cell response [8]. However, the virus persists in 80% of infected 
patients. To boost the immune response, in 1989, interferon-alfa (IFN-α) was first developed, 
and in the decades that followed IFN-α, monotherapy was the standard therapy for hepatitis 
C. While developing the best regimen, various doses and durations of treatment were tested, 
but SVR rates remained modest (15–20%) [8].
The natural history of the HCV does not differ significantly among genotypes. However, HCV 
genotype 3 induces liver steatosis more often than the other genotypes. Patients with differ-
ent genotypes can differ in their response to treatment with recombinant IFN-α and DAAs. 
Treatment efficacy has shown progressive improvement following the pegylation of IFN-α 
and its effect in combination with other antiviral drugs. However, viral escape mechanisms, 
IFN-α signaling in the liver, and substantial drug toxicity still restricted the efficacy of this 
treatment [9]. The restricted efficacy of IFN-α treatments stimulated considerable research 
efforts of academia and industry with the aim of understanding the mechanisms of nonre-
sponse to IFN-α [10]. Recently, numerous studies showed association between genetic vari-
ants near the IFNL3 known as IL28B gene and the response to IFN-α treatments [11]. The 
molecular mechanisms that link genetic variation in the IFNL3 gene locus to the response to 
IFN-α remains to be investigated [12].
Combining IFN-α with ribavirin (RBV) became the new standard therapy in 1998. RBV had 
been used as a monotherapy for CHC in the 1990s, and it was discovered to transiently decrease 
serum alanine aminotransferase (ALT) levels during therapy [13, 14]. Subcutaneously injected 
interferon-α2b (INF-α2b) with daily oral RBV achieved an SVR in 38%. SVR was 54–56% after 
pegylated INF α (PEG-INF) was introduced. Until 2011, when the interferon-free era began, 
hepatitis C was treated with 6–12 months of weekly PEG-INF injections and twice-daily RBV 
tablets [2, 8]. Oral DAAs have simplified treatment procurement and delivery and improved 
HCV treatment outcomes. Numerous trials of interferon-free, oral DAA regimens have 
reported cure rate of more than 85% regardless of HCV genotype, many in only 12 weeks 
[5]. To date, it is assumed that high serum concentrations of IFN-α which are obtained after 
therapy with PEG-INF ensure a crucial advantage compared with nonpegylated forms of 
recombinant IFN-α [9].
In 2014, four classes of DAAs were described: NS3/4A protease inhibitors, non-nucleo-
side polymerase inhibitors, nucleoside/tide polymerase inhibitors, and NS5A inhibitors 
[5]. In general, DAA regimens are better tolerated and more effective than PEG-IFN and 
RBV. Boceprevir and telaprevir—two HCV protease inhibitors—were developed to be given 
in combination with RBV and PEG-IFN. This combination prevented emergence of HCV 
mutants with genetic resistance to the protease inhibitors. For the first time, an SVR could 
be achieved in more than 75% of individuals that were infected with the HCV genotype 1 
[15, 16]. HCV non-nucleoside polymerase inhibitors (dasabuvir) are twice-daily drugs devel-
oped primarily for genotype1 [17, 18]. HCV nucleoside/tide polymerase inhibitors, such as 
sofosbuvir, are taken once daily and generally have a pangenotypic activity, potency, high 
resistance barrier, and low propensity for drug-drug interactions. HCV NS5A  inhibitors 
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(daclatasvir, ledipasvir, and ombitasvir) are novel drug class that are potent and have low 
barrier to resistance (Figure 1). So further research is needed to prevent or overcome drug 
resistance. On the other hand, daclatasvir and ledipasvir are pangenotypic and are well 
suited for combination with other DAAs [16].
4. Approach considerations in the IFN treatment era
Adherence to therapy is one of the most important factors for successful therapy [19]. It is 
important to reduce side effects and motivate patients to adhere to treatment in favor of 
optimizing treatment responses [20]. Due in part to the side effects, the adherence to inter-
feron-based HCV treatment was limited, resulting in dosage reduction and sometimes dis-
continuation of therapy, which led to the frequent virus breakthrough [21]. Historically, the 
most predominant side effects have consisted of “flu”-like symptoms: fatigue, myalgia, fever, 
insomnia, and weakness [22]. Although up to two-thirds of patients complained of fatigue, it 
is important that the clinician distinguishes it from severe anemia, depression, or other meta-
bolic disorders [23]. The “flu”-like symptoms were usually easily managed and did not lead 
to treatment discontinuation. On the other hand, cytopenias, particularly anemia, were the 
most troublesome side-effect, causing drug-dose reduction and early treatment discontinua-
tion [24]. In addition, patients with HCV had other conditions that required treatment with 
medications that could cause hematologic toxicities. For that reason, a multifaceted approach 
was required, such as pretreatment screening, cardiac, and hematologic consultations when 
necessary, frequent laboratory monitoring, and dose reductions [25]. Erythropoietin and 
blood transfusions, as well as aggressive RBV dosage reductions, are effective for managing 
anemia [26].
Various types of dermatologic manifestations, such as dry skin and pruritus, have been 
reported during anti-HCV therapy. Dermatologic side effects seriously affect the skin barrier, 
quality of life, and sleep. A break in the skin can be the point of entry for a bacterial infection. 
Injection site reactions from interferon-based therapies may occur typically characterized by 
Figure 1. HCV Therapeutic Timeline.
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local tenderness, erythema, and itching [27]. It is wise to eliminate any unnecessary medica-
tions before HCV therapy and to recommend good skin hygiene. For patients who develop 
drug-related rash, use of topical antipruritics or systemic antihistamines can be helpful, but 
sometimes dermatology consultation is required for further management [28].
Some of the most frequently reported gastrointestinal symptoms include nausea and dys-
geusia. Patients may minimize nausea by taking RBV with food; however, antiemetics may 
be needed [25]. Dysgeusia is treated by sipping water frequently. To maintain salivary flow 
and oral hygiene, oral ointments and mouth washes are used [29]. Anal discomfort, with 
or without diarrhea, may respond to barrier creams and hemorrhoidal ointments. Patients 
presenting with a rectal bleed and abdominal pain should be worked-up for ischemic colitis, 
which can be diagnosed by CT scan with contrast or colonoscopy [30].
Psychiatric effects of HCV therapy are relatively preventable through symptom monitoring, 
frequent visits to assess clinical improvement, the use of selective serotonin reuptake inhibi-
tors, and IFN dose reduction when needed. Patients who develop severe depression should 
be taken off HCV therapy because suicide has been reported on combination therapy [31]. The 
health care provider should observe symptoms that could be related to depression, such as 
sleep disturbance, irritability, and decreased memory. Early consultation with a psychiatrist 
is of great importance for defining a psychiatric diagnosis, selecting a treatment, and educat-
ing the patient about treatment expectations [32].
There are many ways a health care provider can help the patient manage side effects of the 
treatment. A gentle modification of behavior or routine medical therapy is often the first step, 
followed by dose reduction or adding additional medications. Patients are advised to rest 
when required and to maintain a regular daily schedule. Also, encouraging physical activity 
may help maintain emotional balance and promote energy levels [33]. Maintaining hydration 
is important in boosting a sense of well-being. Providing a support network, such as availabil-
ity of nurses and an after-hours telephone health link, improves adherence to treatment and 
patient satisfaction. Additionally, the right timing and the adequate injection of the PEG-INF 
injection can be helpful [29].
Patient quality of life (QOL) during HCV treatment affects medication adherence [34], which 
is why it is necessary to think broadly about treatment management. In a study conducted by 
Manos et al., serious financial consequences of the HCV treatment (job loss, decreased work 
hours, difficulty paying for medications) were reported by 34.8% patients [35]. Over half of 
the patients reported difficulty attending social functions. When asked to rank how helpful 
different types of support might be for future patients undergoing treatment, the most highly 
ranked options were more frequent provider contact by telephone and peer support availabil-
ity. Overall, patients were more satisfied with a care provided by a nurse or clinical pharma-
cist rather than by physicians. Others have reported frustration with communication among 
physicians and communication between the patient and the physician [36]. Furthermore, a 
common desire among patients was access to multidisciplinary services [35]. Communication 
quality is impacted by the time limitation of providers. To address such limitations, some 
healthcare systems rely on nurse practitioners and physician assistants to care for patients 
with hepatitis C [37]. The importance of nurses in patient QOL during HCV treatment and 
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their support has been rated highly [38]. Mental health providers are also helpful to maintain 
HCV treatment adherence, and a pilot study suggests effectiveness of the weekly telephone 
meetings with a mental health professional [39]. Other studies and guidelines suggest that 
interdisciplinary, integrated care models can help optimizing HCV treatment [40, 41].
In conclusion, the treatment of HCV should be undertaken by physicians with a broad clinical 
knowledge. Close clinical follow-up of patients is needed for early recognition and appropriate 
management of most of the side effects. Prescreening patients for potential clinical problems is 
crucial part of side effects anticipation which leads to involving specialists in a timely manner. The 
HCV provider is able to address side effects and monitor the efficacy of the regimen when patient 
visits twice monthly, at least in the beginning of therapy. Moreover, successful adherence to treat-
ment can be enhanced by a strong support network, which includes specially trained hepatitis 
nurses and a multidisciplinary team consisting of pharmacists, counselors, and social workers.
5. Approach considerations in the IFN-free treatment era
The protease inhibitor boceprevir was approved in 2011, followed by the approval of telapre-
vir [42]. A third protease inhibitor, simeprevir, was approved in 2013 and is recommended 
as a part of combination therapy for chronic HCV infection. More recently, NS5B polymerase 
inhibitor sofosbuvir has emerged as an important component of currently recommended reg-
imens [43]. In 2014, the FDA approved an all-oral regimen of simeprevir plus sofosbuvir for 
treatment-naïve or treatment-experienced patients [44]. DAAs are effective regardless of race, 
gender, or HIV status [45, 46]. They have few side effects, short durations of treatment, and 
high SVRs. Therefore, DAAs have the potential to lower mortality, improve QOL, and reduce 
long-term costs of complications in HCV infected individuals [47]. This is why every patient 
with chronic HCV infection should be considered for antiviral treatment with DAA agents, 
even if previous interferon-based therapy has failed [48].
There are certain settings where limited access to medications forces health practitioner to decide 
which patient should be treated first. In circumstances like this, practitioners rely on evidence-
based medicine and guidelines. Treatment for CHC is based on guidelines from the Infectious 
Diseases Society of America (IDSA) and the American Associations for the Study of Liver Diseases 
(AASLD) [49]. Recommendations are evidence based and are constantly updated as new data 
from peer-reviewed evidence become available. The guidelines propose that treatment priority 
should be given to those with the most urgent need. The recommendations include the following:
1. The highest priority for treatment should be given to the patients with advanced fibrosis, 
compensated cirrhosis, and severe extrahepatic hepatitis, as well as liver transplant recipients.
2. Patients with high priority for treatment are the ones at high risk for liver-related compli-
cations and severe extrahepatic hepatitis C complications.
3. Certain subgroups of HCV patients, such as men who have high-risk sex with men, active 
injection drug users, incarcerated persons, and those on hemodialysis are patients whose 
risk of HCV transmission is high, and in whom, HCV treatment may result in a reduction in 
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transmission. In those patients, treatment decisions should balance the anticipated reduction 
in transmission versus the likelihood of reinfection.
Although antiviral therapy for CHC should be determined on a case-by-case basis, treatment 
is widely recommended for patients with elevated ALT levels who meet the following criteria 
[50]: older than 18 years, positive HCV antibody and serum HCV RNA, compensated liver 
disease, adequate hematologic and biochemical indices, willingness, and adherence to treat-
ment, without contraindications.
In Europe, EASL Recommendations on Treatment of Hepatitis C assist physicians and other 
healthcare providers in the clinical decision-making process by providing information about the 
current optimal management of patients with acute and chronic HCV infections [51]. The recom-
mendations have been based on evidence from existing publications and presentations at inter-
national meetings and the expert personal experiences. According to EASL, all treatment-naïve 
and treatment-experienced patients with compensated or decompensated chronic liver disease 
related to HCV, who have no contraindications to treatment, must be considered for therapy. The 
treatment must be available without delay in patients with significant fibrosis or cirrhosis, includ-
ing decompensated cirrhosis; patients with clinically significant extrahepatic manifestations 
(e.g., symptomatic vasculitis, mixed cryoglobulinemia, nephropathy, and non-Hodgkin B-cell 
lymphoma); patients with HCV recurrence after liver transplantation; patients with concurrent 
comorbidities who are at risk of a rapid evolution of liver disease (non-liver solid organ or stem 
cell transplant recipients, diabetes); and individuals at risk of transmitting HCV (active injection 
drug users, men who have sex with men with high-risk sexual practices, women of childbearing 
age who wish to get pregnant, hemodialysis patients, incarcerated individuals) [51].
Prior to initiating DAA therapy, patients should undergo a thorough pre-treatment evaluation, 
which includes identifying the genotype of hepatitis C, evidence of cirrhosis, and previous treat-
ment. Comorbid physical or psychological conditions should be optimized before commencing 
therapy because it will improve compliance. Evaluation for advanced fibrosis is recommended 
for all persons with HCV infection [49]. Another important consideration before starting therapy 
is the possibility of drug-drug interactions, as well as severe renal impairment [48].
Treatment of chronic HCV infection has two goals: to achieve SVR and to prevent progression 
of cirrhosis, hepatocellular carcinoma, and decompensated liver disease which can lead to the 
liver transplantation [49]. Patients who achieve an SVR experience numerous health benefits, 
including a decrease in liver inflammation levels, a reduction in the rate of progression of 
liver fibrosis [52], and reduced symptoms and mortality from severe extrahepatic manifesta-
tions [53]. Patients with normal liver function tests after SVR can be managed as if they had 
never been infected with HCV. Individuals who have failed to achieve SVR must be given an 
opportunity to pursue further therapeutic options [48].
6. Approach considerations in the near future
Currently, access to treatment for HCV is limited, with only a minority diagnosed patients, 
and even fewer assessed are initiated on treatment [54]. HCV therapy has the potential to 
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ensure individual and health benefits, but high prices have stopped access to HCV therapy, 
even in high income countries and to people with advanced liver disease. If DAAs are to stop 
HCV-related mortality and decrease the global burden of HCV infection in the coming years, 
current HCV treatment rates of 1% to <5% must be increased [55]. Treating patients with 
fibrosis will decrease morbidity and mortality of HCV, but unless patients without advanced 
liver disease are treated too, the epidemic of HCV will continue [56].
7. Conclusion
Key desirable characteristics of the HCV therapy include high efficacy, tolerability, pan-geno-
typic activity, short duration, oral administration, affordability, and fixed-dose combination. 
The major reasons for limited treatment access are the cost, complexity, and limited effec-
tiveness of treatment, as well as lack of access to reliable and affordable diagnostics. The 
improved safety profile and improved efficacy across genotypes of the new DAAs make the 
pre-treatment screening simple. In the future, HCV treatment could be initiated immediately 
after confirmation of infection and the presence of viremia, with only an initial assessment of 
the stage of liver disease. Future development of pan-genotypic regimens with minimal side 
effects that will be available at an affordable price holds the greatest potential for expanding 
access to treatment to all HCV patients.
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